Logo

Celltrion's Herzuma (trastuzumab- biosimilar) Receives ANVISA's Approval for Breast and Gastric Cancer in Brazil

Share this
Celltrion's Herzuma (trastuzumab- biosimilar) Receives ANVISA's Approval for Breast and Gastric Cancer in Brazil

Celltrion's Herzuma (trastuzumab- biosimilar) Receives ANVISA's Approval for Breast and Gastric Cancer in Brazil

Shots:

  • The Brazilian Health Regulatory Agency- ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved Herzuma (trastuzumab) in 150mg & 440mg for early-stage breast cancer- metastatic breast cancer and metastatic gastric cancer on May 20- 2019
  • Celltrion is also expecting ANVISA’s approval for Truxima- a biosimilar of Rituximab which helps in securing a leading market position in the Central-South American biosimilar market
  • Herzuma (trastuzumab-pkrb) is a biosimilar of Herceptin and has received FDA’s approval in Dec’18- also approved in EU (marketed by Mundipharma)- in Japan (marketed by Daiichi Sankyo) and in Australia

Ref: Celltrion | Image: Celltrion

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions